A randomised, double-blind, efficacy and dose finding study of intermittent preventive treatment with dihydroartemisinin-piperaquine for prevention of malaria

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN65524939

Enrollment

780

Registered

2006-08-08

Start date

2006-08-15

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plasmodium falciparum malaria Infections and Infestations Plasmodium falciparum malaria

Interventions

Intermittent Preventive Treatment (IPT) of dihydroartemisinin and piperaquine versus a placebo.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Male 2. Aged over 18 years 3. Willingness to attend for follow up for nine months 4. Written informed consent given to participate in the trial

Exclusion criteria

Exclusion criteria: 1. Malaria asexual stage parasitaemia 2. Dapsone Pyrimethamine (DP) treatment within the past six months 3. Mefloquine treatment within the past two months 4. Known hypersensitivity to artemisinins or DP

Design outcomes

Primary

Measure	Time frame
Incidence of malaria	—

Secondary

Measure	Time frame
Safety	—

Countries

Thailand

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026